Luyang Yao

The University of Texas MD Anderson Cancer Center

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 2 papers. Top paper: “Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial”.

Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial

Lung Cancer(2022)10.1016/j.lungcan.2022.10.006

N/A

0.529DataRank · unranked

33 citations

Luyang Yao, Neda Kalhor, Brett W. Carter, Mehmet Altan, George Blumenschein +14 more

A mid-chemoradiation dynamic risk model integrating tumor features and ctDNA analysis for lung cancer outcome prediction.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.9046

N/A

0.104DataRank · unranked

1 citations

Mohammad Shahrokh Esfahani, Barzin Y. Nabet, Yufei Liu, Jacob J. Chabon, Jianzhong He +15 more